Amarin (AMRN) CEO Lynch To Step Down, Remains Chairman
More News related to AMRN
- Amarin Announces Notice of Annual General Meeting
- Amarin Corp Is First Small Biopharmaceutical Company to Join SAFE-BioPharma Association
- Amarin Appoints John F. Thero as Chief Financial Officer
- Amarin Announces Completion of $70 Million Private Placement
- Amarin Appoints Medpace as CRO for Two Phase 3 Cardiovascular Trials
More News related to Management Changes
- Hydrogenics Resumes Trading Under NASDAQ Symbol "HYGS"
- Varian Medical (VAR) to Highlight its New Range of Detectors at Annual RSNA Meeting in Chicago
- Manulife (MFC) Confirms No Exposure to Dubai World
- Activision's (ATVI) Call of Duty Amasses $3 Billion in Global Sales
- Seiko Epson to Transfer Sales Function of Small and Medium-Sized TFT LCD Business to Sony (SNE)
Amarin Corporation plc (NASDAQ: AMRN) said after the closing of the $70 million private placement announced today, Mr. Thomas Lynch, Chairman and Chief Executive Officer of Amarin, has decided he will step down as CEO and will continue as Chairman.
Dr. Declan Doogan, Amarin's Head of Research and Development, has agreed to assume the role of Interim CEO.
Related Categories
Management ChangesStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
